Opendata, web and dolomites

CAN-IT-BARRIERS SIGNED

Disruption of systemic and microenvironmental barriers to immunotherapy of antigenic tumors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAN-IT-BARRIERS project word cloud

Explore the words cloud of the CAN-IT-BARRIERS project. It provides you a very rough idea of what is the project "CAN-IT-BARRIERS" about.

expressing    frontier    mostly    unprecedented    breaking    genetically    antigens    lack    presenting    stimulatory    microenvironment    tumor    concert    refractory    infiltration    mediated    therapy    faceted    lies    producing    oncogene    hpv    impairing    immunosuppression    combined    efficacy    mechanisms    complemented    antigen    cells    erect    therapeutic    responsive    cytotoxic    types    turn    dendritic    systemic    lab    immunogenic    tumors    groundwork    poorly    actionable    immunotherapies    spectrum    immuno    immune    patients    survival    modalities    cancer    induction    lymph    ctls    orchestrating    eliminating    elicit    overarching    spleen    basis    expanded    encode    efficacious    nodes    cd8    human    barriers    populations    keratinocytes    strategies    helping    adaptive    killing    papillomavirus    solid    ostensibly    ll    multiple    probe    attack    infiltrating    immunosuppressive    e6    immunotherapy    operative    manifestation    expansion    circumvent    inhibit    nonspecific    benefit    establishing    myeloid    mouse    pharmacologically    priori    reactive    alone    functional    oncoproteins    hypothesis    barrier    activation    expression    models    tumorigenesis    cancers    marked    resistance    corollary    oncogenes    lay    neo   

Project "CAN-IT-BARRIERS" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 2˙500˙000.00

Map

 Project objective

The frontier in cancer therapy of orchestrating the immune system to attack tumors is producing unprecedented survival benefit in some patients. The corollary is lack of efficacy both in ostensibly responsive tumor types as well as others that are mostly non-responsive. The basis lies in pre-existing and adaptive resistance mechanisms that circumvent induction of tumor-reactive cytotoxic T cells (CTLs) capable of infiltrating solid tumors and eliminating cancer cells. A priori, cancers induced by expression of human papillomavirus oncogenes should be responsive to immunotherapy: these cancers encode immunogenic neo-antigens – the oncoproteins E6/7 – necessary for their manifestation. Rather, such tumors are poorly responsive to immunotherapies. Results from my lab and others using mouse models of HPV-induced cancer have established an actionable hypothesis: during tumorigenesis, such tumors erect multiple barriers to the induction, infiltration, and killing of cancer cells by tumor antigen-reactive CTLs. These include overarching systemic antigen-nonspecific immunosuppression mediated by expanded populations of myeloid cells in spleen and lymph nodes, complemented by immune response-impairing barriers operative in the tumor microenvironment. A spectrum of models will probe these barriers, genetically and pharmacologically, establishing their functional importance, alone and in concert. A major focus will be on how oncogene-expressing keratinocytes elicit a marked expansion of immunosuppressive myeloid cells in spleen and lymph nodes, and how these myeloid cells in turn inhibit development and activation of CD8 T cells and antigen-presenting dendritic cells. Then we’ll assess the therapeutic potential of barrier-breaking strategies combined with immuno-stimulatory modalities. This project will deliver new knowledge about multi-faceted barriers to immunotherapy in these refractory cancers, helping lay the groundwork for efficacious immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAN-IT-BARRIERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAN-IT-BARRIERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More